thiazolidinedione

(redirected from Ciglitazone)
Also found in: Dictionary.

gli·ta·zone

(glit-ah'zōn),
Shorthand term for a class of oral hypoglycemics that have glitazone as a component in their names.
Synonym(s): thiazolidinedione
Farlex Partner Medical Dictionary © Farlex 2012

thiazolidinedione

(thī′ə-zō′lĭ-dēn′dĭ-ōn′)
n.
Any of a class of drugs that decrease insulin resistance and are used to treat type 2 diabetes.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

thiazolidinedione

Glitazone, TZD Endocrinology A class of oral antidiabetic agents that inhibit tyrosine kinase, ↓ insulin resistance and correct hyperglycemia, hyperinsulinemia, hypertriglyceridemia Adverse effects Hepatic dysfunction. See Troglitazone, Tyrosine kinase inhibitor.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

thiazolidinedione

(thī′ă-zŏ″lĭ-dēn-dī-ŏn)
A class of oral hypoglycemic agents that lowers blood sugars by reducing insulin resistance (improving tissue sensitivity to the effects of insulin) in fat and muscle, as well as the liver. A commonly used agent in this class is pioglitazone.

CAUTION!

Side effects of medications in this class include increased fluid retention, fractures, heart failure, liver injury, and weight gain.
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Kim et al., "Cell death is induced by ciglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, independently of PPARgamma in human glioma cells," Biophysical Research Communications, vol.
The use of ciglitazone, a PPAR[gamma] agonist, in normoxia did not lead to PGC reprogramming (Figure 1(d)), indicating that PPAR[gamma] alone is unable to provoke a metabolic shift that, in turn, induces PGC reprogramming.
The expression of PPAR[gamma] in gastric cancer tissue was reported to be markedly reduced compared to its expression in normal tissue (19), and recent studies have indicated that apoptosis is induced following the administration of PPAR[gamma] ligands such as ciglitazone or 15-deoxy-12, 14-prostaglandin J2 (15dPGJ2) in the colorectal carcinoma cell lines HT-29 and Colo-205 (20), and in MCG-803 human gastric cancer cells (21).
Twenty-four hours after cells reached 100% confluence, cells were differentiated by 72 hours of treatment in preadipocyte differentiation medium containing no serum, 8 [micro]g/mL d-biotin, 0.5 [micro]g/mL insulin, 400 ng/mL dexamethasone, 44 [micro]g/mL 3-isobutyl-1-methylxanthin (IBMX), 9 ng/mL L-thyroxine, and 3 [micro]g/mL ciglitazone (PromoCell) with or without 1 g/L fructose.
Similar expression pattern was observed after treatment of ciglitazone to porcine satellite cells by Singh et al.
N-Acetylcysteine (NAC), vitamin E [[alpha]-tocopherol (AT)], catechin, epigallocatechin gallate (EGCG), ciglitazone, and lovastatin were obtained from Sigma Chemical Company.
Englitazone, ciglitazone, and pioglitazone are the newest additions to this family of drugs, and are currently under study in clinical trials (Bajaj & Simonson, 1997; Janeway et al., 1998).
The TZDs rosiglitazone, pioglitazone, and ciglitazone, all resulted in a decrease of myocardial infarct size.
Ciglitazone, a peroxisome proliferator-activated receptor c (PPARc), mediates PPARc activation and moderates the activation of AMPK, causing a decrease in the expression of LOX-1.
Certain members of the thiazolidinediones family of the peroxisome proliferator-activated receptor (PPAR[gamma]) agonists, such as TG and ciglitazone, possess a beneficial action against ROS, inflammation, and adipocytokine dysregulation [23, 24].
The most significant position of these molecules seems to be as they are a subset of commercially employed noninsulin-dependent diabetes mellitus (NIDDM), insulin sensitizing agents (Figure 1) such as epalrestat, ciglitazone, AD-5061, pioglitazone, rosiglitazone, and so forth.
2006) and the peroxisome proliferator-activated receptor-[gamma] ligand ciglitazone (Chen and Harrison 2005), both xenobiotics that induce NF-[kappa]B activation, have been shown to include p65 phosphorylation.